-transparent.png){kind=logo}
Vigabatrin (gamma-vinyl-GABA or GVG) is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), which is an enzyme responsible for gamma-aminobutyric acid (GABA) catabolism. Inhibition of GABA catabolism increases brain concentration of GABA, a neural inhibitor. GVG has been found to be a potent new anti-epileptic drug, especially in the treatment of refractory epilepsy, in particular of complex partial seizures. Three patients who developed a severe status epilepitus while on GVG treatment are reported. A possible proconvulsive effect of GVG is hypothesized, which might result from disinhibition in the nigro-collicular pathway due to increased GABA-levels.
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
July 2009,
Revista medica de Chile,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
December 2003,
Epilepsy & behavior : E&B,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
April 1975,
The Medical journal of Australia,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
December 2001,
Psychiatry and clinical neurosciences,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
March 1994,
Neurologia (Barcelona, Spain),
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
December 2020,
Journal of epilepsy research,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
July 2021,
Seizure,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
April 1999,
The Journal of reproductive medicine,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
April 1987,
The Journal of reproductive medicine,
M C de Krom, and
N Verduin, and
E Visser, and
M Kleijer, and
F Scholtes, and
J H De Groen
January 1991,
Rivista di neurologia,
